Silexion Therapeutics Corp
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
SLXN$0.11-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
| September 30, | December 31 | |
|---|---|---|
| 2024 | 2023 | |
| U.S. dollars in thousands | ||
| Assets | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $1,973 | $4,595 |
| Restricted cash | 50 | 25 |
| Prepaid expenses | 944 | 335 |
| Other current assets | 80 | 24 |
| TOTAL CURRENT ASSETS | 3,047 | 4,979 |
| NON-CURRENT ASSETS: | ||
| Restricted cash | - | 25 |
| Long-term deposit | 5 | 5 |
| Property and equipment, net | 35 | 49 |
| Operating lease right-of-use asset | - | 198 |
| TOTAL NON-CURRENT ASSETS | 40 | 277 |
| TOTAL ASSETS | $3,087 | $5,256 |
F - 3
| September 30, · December 31 | |||
|---|---|---|---|
| 2024 · 2023 | |||
| U.S. dollars in thousands | |||
| Liabilities and redeemable convertible preferred shares, net of capital deficiency | |||
| CURRENT LIABILITIES: | |||
| Trade payables | $799 | $319 | |
| Current maturities of operating lease liability | - | 112 | |
| Warrants to preferred shares (including $0 and $186 due to related party, as of September 30, 2024 and December 31, 2023, respectively) | - | 200 | |
| Employee related obligations | 687 | 207 | |
| Accrued expenses and other account payable | 1,858 | 1,358 | |
| Private warrants to purchase ordinary shares | 10 | - | |
| Underwriters Promissory Note | 229 | - | |
| TOTAL CURRENT LIABILITIES | 3,583 | 2,196 | |
| NON-CURRENT LIABILITIES: | |||
| Long-term operating lease liability | - | 59 | |
| Underwriters Promissory Note | 977 | - | |
| Promissory note - related party | 3,106 | - | |
| TOTAL NON-CURRENT LIABILITIES | $4,083 | $59 | |
| TOTAL LIABILITIES | $7,666 | $2,255 | |
| COMMITMENTS AND CONTINGENT LIABILITIES | |||
| REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS: | |||
| Convertible Series A Preferred Shares (NIS 0.01 par value, 0 and 510,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0 and 388,088 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively); | |||
| Convertible Series A-1 Preferred Shares (NIS 0.01 par value per share, 0 and 120,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0 and 91,216 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively); | |||
| Convertible Series A-2 Preferred Shares (NIS 0.01 par value per share, 0 and 200,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0 and 45,458 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively); | |||
| Convertible Series A-3 Preferred Shares (NIS 0.01 par value per share, 0 and 80,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively 0 and 63,331 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively); | |||
| Convertible Series A-4 Preferred Shares (NIS 0.01 par value per share, 0 and 815,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0 and 21,717** shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively); | |||
| TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES | - | 15,057 | |
| CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS | - | 3,420 | |
| TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS | $ | - | $18,477 |
F - 4
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| U.S. dollars in thousands | ||
| CAPITAL DEFICIENCY: | ||
| Ordinary shares ($0.0001 par value per share, 200,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 11,180,031 and 873,665 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively) | 1 | * |
| Additional paid-in capital | 37,003 | 11,335 |
| Accumulated deficit | (41,583) | (26,811) |
| TOTAL CAPITAL DEFICIENCY | $(4,579) | $(15,476) |
| TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY | $(4,579) | $3,001 |
| TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY | $3,087 | $5,256 |
** Net of 121,119 treasury shares held by the subsidiary as of December 31, 2023
F - 5
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.